NeuroScientific Biopharmaceuticals (NSB) Q4 2025 TU earnings summary

Executive summary

• Acquired 100% of Isopogen WA Ltd, securing rights to the patented StemSmart mesenchymal stem cell (MSC) technology.

• Appointed Robert McKenzie as Chair and Paul Fry as non-executive director; Marian Sturm to become Chief Scientific Officer.

• Focused on launching a Special Access Program for fistulising Crohn's disease using StemSmart MSCs.

Financial highlights

• Cash balance of A$7.3 million as of 30 June 2025.

• Raised $3.5 million via a placement to institutional and professional investors.

• Quarterly R&D payments were $50k, staff costs $88k, and admin/corporate costs $261k.

• Received $320k R&D Tax Incentive rebate after quarter end.

Outlook and guidance

• Immediate focus on the Special Access Program for fistulising Crohn's disease, with plans to progress to a Phase 1/2 clinical trial if successful.

• Targeting regulatory and reimbursement approvals for MSC therapy in Australia and globally.